Kiniksa Pharmaceuticals Ltd (KNSA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.40B
Last updated: Nov 17, 2026 at 4:38 PM ET
Kiniksa Pharmaceuticals Ltd (KNSA) Statistics
Kiniksa Pharmaceuticals (KNSA) has a market cap of $7.40B and an enterprise value of $7.32B. Revenue grew 58.19% over the last 12 months from the 12 months before. Its share count is up 4.65% from a year earlier.
Total Valuation
Enterprise value is 1.10% below the market cap, as cash exceeds debt.
| Market Cap | $7.40B |
|---|---|
| Enterprise Value | $7.32B |
| Latest price (Nov 17, 2026) | $95.11 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 27, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 7.9x and 10.5x. Its year-end P/E ranged from 5.8x to 97.4x from 2022 to 2025.
| P/E Ratio | 73.2x |
|---|---|
| Forward P/E | 72.5x |
| P/S Ratio | 7.9x |
| Forward P/S | 7.1x |
| P/B Ratio | 10.5x |
| P/TBV Ratio | 10.7x |
| P/FCF Ratio | 37.7x |
| P/OCF Ratio | 37.2x |
| PEG Ratio | 2.0 |
Enterprise Valuation
Counting debt and cash, the company is valued at 49.6x EBITDA and 37.3x free cash flow.
| EV / Earnings | 66.8x |
|---|---|
| EV / Sales | 7.7x |
| EV / EBITDA | 49.6x |
| EV / EBIT | 50.1x |
| EV / FCF | 37.3x |
Price Statistics
The stock is up 135.89% over 52 weeks and trades 14.78% above its 50-day average.
| Beta (1Y) | 0.60 |
|---|---|
| 52-Week Change | +135.89% |
| 1-Month Change | +19.67% |
| 3-Month Change | +17.71% |
| 6-Month Change | +78.31% |
| 5-Year Change | +787.78% |
| Total Return (1Y) | +135.89% |
| Total Return (3Y CAGR) | +82.23% |
| Total Return (5Y CAGR) | +49.79% |
| Return vs SPY (1Y) | +118.84% |
| Max Drawdown (1Y) | -21.12% |
| Max Drawdown (3Y) | -34.14% |
| Sharpe Ratio (1Y) | 1.57 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $82.86 |
| 200-Day Average | $63.33 |
| 52-Week Range | $37.02 to $99.31 |
| RSI (14 Days) | 58.0 |
| Average Volume (20 Days) | 908.54K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.91x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.91x |
|---|---|
| Quick Ratio | 3.35x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 15.43% over the last 12 months, against a 5-year average of -7.06%.
| Return on Equity (ROE) | 15.43% |
|---|---|
| Return on Assets (ROA) | 11.14% |
| Return on Capital Employed (ROCE) | 18.47% |
| ROE (5Y Average) | -7.06% |
| ROA (5Y Average) | -5.00% |
| ROIC (5Y Average) | 10.40% |
| Asset Turnover | 1.12x |
| Inventory Turnover | 4.83x |
| Receivables Turnover | 34.86x |
| Cash Conversion Cycle | 79 days |
Taxes
Income tax took 25.03% of pretax income over the last 12 months.
| Income Tax (TTM) | $36.58M |
|---|---|
| Effective Tax Rate | 25.03% |
Scores
KNSA has an Altman Z-Score of 17.95, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 17.95 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $945.96M over the last 12 months.
| Revenue | $945.96M |
|---|---|
| Revenue Growth (YoY) | +58.19% |
| Gross Profit | $513.39M |
| Operating Income | $130.47M |
| Pretax Income | $146.15M |
| Net Income | $109.57M |
| EBITDA | $148.17M |
| EBIT | $146.15M |
| Reported EPS (TTM) | $1.30 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.23% of the $983.24M in total assets.
| Cash and Equivalents | $81.66M |
|---|---|
| Total Debt | $0 |
| Net Cash | $81.66M |
| Net Cash Per Share | $1.04 |
| Working Capital | $558.24M |
| Shareholder Equity | $710.19M |
| Book Value Per Share | $9.08 |
| Tangible Book Value | $695.69M |
| Tangible Book Per Share | $8.90 |
| Total Assets | $983.24M |
| Total Liabilities | $273.05M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.64M of capital spending, operating cash flow left $197.20M of free cash flow.
| Operating Cash Flow | $198.84M |
|---|---|
| Capital Expenditures | $1.64M |
| Free Cash Flow | $197.20M |
| FCF Per Share | $4.08 |
| Depreciation and Amortization | $4.56M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 13.79%, against a 5-year average of -82.13%.
| Gross Margin | 54.27% |
|---|---|
| Operating Margin | 13.79% |
| Pretax Margin | 15.45% |
| Net Margin | 11.58% |
| EBITDA Margin | 15.66% |
| EBIT Margin | 15.45% |
| FCF Margin | 20.85% |
| Gross Margin (5Y Average) | 65.91% |
| Operating Margin (5Y Average) | -82.13% |
| Net Margin (5Y Average) | -64.55% |
Growth
Revenue grew 45.45% a year over 3 years, and EPS fell 34.14% a year.
| Revenue Growth (3Y CAGR) | +45.45% |
|---|---|
| EPS Growth (3Y CAGR) | -34.14% |
| FCF Growth (3Y CAGR) | +188.15% |
| Operating Income Growth (3Y CAGR) | +99.18% |
| Book Value Per Share Growth (2Y CAGR) | +9.08% |
| Tangible Book Per Share Growth (2Y CAGR) | +9.79% |
Dividends and Yields
KNSA does not pay a dividend. Its free cash flow yield is 2.65%.
| Earnings Yield | 1.37% |
|---|---|
| FCF Yield | 2.65% |
| Buyback Yield | -0.52% |
| Shareholder Yield | -0.52% |
Peer Position
Against 10 similar companies, KNSA has the 2nd highest P/E.
P/E RatioPeer median 19.9x
P/S RatioPeer median 3.0x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +11.47%
| P/E Ratio | 73.2x vs 19.9x median |
|---|---|
| P/S Ratio | 7.9x vs 3.0x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +58.19% vs +11.47% median |
Analyst Forecast
Consensus estimates put revenue growth at 39.84% and EPS growth at 71.74% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +39.84% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +71.74% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About KNSA
What is KNSA's market cap?
Kiniksa Pharmaceuticals has a market cap of $7.40B. Its enterprise value, which adds debt and subtracts cash, is $7.32B.
What is KNSA's P/E ratio?
Kiniksa Pharmaceuticals has a trailing P/E ratio of 73.2x and a forward P/E of 72.5x.
How many shares of KNSA are outstanding?
Kiniksa Pharmaceuticals has 78.19M shares outstanding. The count is up 4.65% from a year earlier.
Does KNSA pay a dividend?
No. Kiniksa Pharmaceuticals does not pay a dividend.
How much debt does KNSA have?
Kiniksa Pharmaceuticals has $0 of total debt and $81.66M of cash and equivalents, a net cash position of $81.66M.
KNSA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts